Sanofi (SNY)
Sanofi (SNY) is a healthcare company (drug manufacturers - general) based in France. The share price is $47.70, down 1.44% on the day, which values the company at $114.53B. Price as of 17 Nov 2026, 19:09 UTC, from Yahoo Finance.
Key facts
- Share price
- $47.70−1.44% today
- Market value
- $114.53B
- P/E ratio
- 23.7×last 12 months
- Forward P/E
- 8.8×
- Funk Score
- 65/100
- 200-week average
- $49.393% below
- Sector
- Healthcare
Figures as of . Prices from Yahoo Finance (may be delayed); statements from company filings with the SEC and Yahoo Finance. Estimates, not advice.
Sanofi in more detail
SNY trades at 23.7× its last twelve months' earnings, 8.8× next year's expected earnings, 2.2× sales. It sits 3% below its 200-week average of $49.39.
Its Funk Score is 65 out of 100 (financial strength 7.4, profitability 5.4, growth 6.7, each out of 10).
In its favour: Strong Piotroski score; Share count keeps falling.
7 of the superinvestors tracked here hold SNY, including Charles Brandes (founder) (1.2% of the portfolio), Louis Bacon (0.5% of the portfolio), Sarah Ketterer (0.4% of the portfolio).
Superinvestors holding SNY
7 of the investors tracked here report a position in their latest 13F filing.
- Charles Brandes (founder) Brandes Investment Partners1.22% of portfolio · $177.5M · added · Q3 2026
- Louis Bacon Moore Capital Management0.45% of portfolio · $15.9M · added · Q3 2026
- Sarah Ketterer Causeway Capital Management0.36% of portfolio · $31.6M · trimmed · Q3 2026
- Dodge & Cox team Dodge & Cox0.35% of portfolio · $646M · trimmed · Q3 2026
- Ken Fisher Fisher Investments0.11% of portfolio · $395.7M · trimmed · Q3 2026
- Lee Ainslie Maverick Capital0.02% of portfolio · $2.2M · added · Q2 2026
- Richard Pzena Pzena Investment Management0.01% of portfolio · $4.7M · added · Q3 2026
Health Care companies of similar size
- DanaherDHR
- Intuitive SurgicalISRG
- Vertex PharmaceuticalsVRTX
- MedtronicMDT
- Bristol-Myers SquibbBMY
- StrykerSYK
- McKessonMCK
- ModernaMRNA
- CVS HealthCVS
- HCA HealthcareHCA
- GSKGSK
- Regeneron PharmaceuticalsREGN
Side by side:SNY vs MRNA (Sanofi vs Moderna)SNY vs MCK (Sanofi vs McKesson)SNY vs CVS (Sanofi vs CVS Health)SNY vs SYK (Sanofi vs Stryker)SNY vs HCA (Sanofi vs HCA Healthcare)
All health care companies by market valueLargest companies in FranceAll stocks A–Z
Sanofi (SNY): questions and answers
What is SNY's P/E ratio?
Sanofi trades at 23.7× its last twelve months' earnings and 8.8× next year's expected earnings.
What is SNY's PEG ratio?
Sanofi's PEG ratio is 1.78 — its P/E divided by its expected earnings growth. Around 1 is the classic sign of a price that matches the growth; well above it means the growth is being paid for in advance.
What is Sanofi's market cap?
Sanofi is valued at $114.53B at a share price of $47.70.
Is SNY above its 200-week moving average?
No. SNY is 3.4% below its 200-week average of $49.39. Long-term investors watch that line because strong companies rarely trade below it for long.
How fast is Sanofi growing?
Over the last three fiscal years Sanofi's revenue grew 4.8% a year and its earnings per share 6.0% a year.
Does SNY pay a dividend?
Sanofi does not currently pay a regular dividend.
Learn to read these numbers
All stocks guides →- Altman Z-score: formula, zones and where it fails
The Altman Z-score is a weighted sum of five financial ratios that Edward Altman fitted in 1968 to separate companies that went bankrupt from those that did not. Funkfolio reads above 2.99 as the safe zone, below 1.81 as the distress zone, and between them a grey zone. It does not suit banks or insurers.
- Analyst price targets and ratings: what they mean
An analyst price target is a research analyst's estimate of where a share price will be at a set horizon, such as twelve months; a rating such as buy or hold is that analyst's recommendation. A consensus is an average or median of the targets a data provider has collected. Studies have found targets on average well above later prices.
- Free cash flow and FCF yield explained
Free cash flow is the cash a business generates from operations minus what it spends on equipment, buildings and other long-lived assets. Free-cash-flow yield divides that cash by the company's market value: $5 billion of free cash flow on a $100 billion company is a 5% yield. It is cash available to owners and lenders, not profit.
Cite this page
Funkfolio, “Sanofi (SNY) stock: price, valuation and fundamentals”, data as of 17 November 2026. https://funkfolio.com/stock/SNY
Underlying data: Yahoo Finance; company filings with the SEC.